A Randomized, Single-Blind, Parallel Group, Placebo-Controlled, Dose Rate Escalation Study Evaluating the Safety and Effects of MN-221 [bedoradrine] in Subjects Diagnosed With Moderate to Severe Asthma.

Trial Profile

A Randomized, Single-Blind, Parallel Group, Placebo-Controlled, Dose Rate Escalation Study Evaluating the Safety and Effects of MN-221 [bedoradrine] in Subjects Diagnosed With Moderate to Severe Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2012

At a glance

  • Drugs Bedoradrine (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Nov 2012 Results published in the the Journal of Asthma, according to a MediciNova media release.
    • 02 Mar 2011 Status changed from active, no longer recruiting to completed.
    • 28 Oct 2010 Data were presented at the 2010 Annual Meeting of the American College of Chest Physicians, according to a MediciNova media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top